Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...
Zacks Investment Research on MSN
Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.
Des Moines' Lua Brewing has once again claimed the top spot as the No.1 brewpub in the country in the USA TODAY 10BEST Readers' Choice Awards.
A Des Moines microbrewery is a finalist for the best brewpubs across the U.S., and Iowans have a chance to vote it into the top 10. Lua Brewing was nominated for USA TODAY 10Best's Readers' Choice ...
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results